Literature DB >> 26725321

Suppressor of cytokine signaling 1-dependent regulation of the expression and oncogenic functions of p21(CIP1/WAF1) in the liver.

M Yeganeh1, Y Gui1, R Kandhi1, D Bobbala1, W-S Tobelaim2, C Saucier2, A Yoshimura3, G Ferbeyre4, S Ramanathan1, S Ilangumaran1.   

Abstract

The SOCS1 gene coding for suppressor of cytokine signaling 1 is frequently repressed in hepatocellular carcinoma (HCC), and hence SOCS1 is considered a tumor suppressor in the liver. However, the tumor-suppressor mechanisms of SOCS1 are not yet well understood. SOCS1 is known to inhibit pro-inflammatory cytokine production and signaling and to promote activation of the p53 tumor suppressor. However, we observed that SOCS1-deficient mice developed numerous and large liver tumor nodules following treatment with the hepatocarcinogen diethylnitrosamine (DEN) without showing increased interleukin-6 production or activation of p53. On the other hand, the livers of DEN-treated Socs1-null mice showed elevated levels of p21(CIP1/WAF1) protein (p21). Even though p21 generally functions as a tumor suppressor, paradoxically many cancers, including HCC, are known to express elevated levels of p21 that correlate with poor prognosis. We observed elevated p21 expression also in the regenerating livers of SOCS1-deficient mice and in cisplatin-treated Socs1-null hepatocytes, wherein the p21 protein showed increased stability. We show that SOCS1 interacts with p21 and promotes its ubiquitination and proteasomal degradation. Besides, the DEN-treated livers of Socs1-null mice showed increased nuclear and cytosolic p21 staining, and the latter was associated with growth factor-induced, phosphatidylinositol 3-kinase-dependent phosphorylation of p21 in SOCS1-deficient hepatocytes. Cytosolic p21 is often associated with malignancy and chemo-resistance in many cancers. Accordingly, SOCS1-deficient hepatocytes showed increased resistance to apoptosis that was reversed by shRNA-mediated p21 knockdown. In the regenerating livers of Socs1-null mice, increased p21 expression coincided with elevated cyclinD levels. Correspondingly, SOCS1-deficient hepatocytes showed increased proliferation to growth factor stimulation that was reversed by p21 knockdown. Overall, our findings indicate that the tumor-suppressor functions of SOCS1 in the liver could be mediated, at least partly, via regulation of the expression, stability and subcellular distribution of p21 and its paradoxical oncogenic functions, namely, resistance to apoptosis and increased proliferation.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26725321     DOI: 10.1038/onc.2015.485

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  46 in total

1.  Is p21 an oncogene?

Authors:  Andrei L Gartel
Journal:  Mol Cancer Ther       Date:  2006-06       Impact factor: 6.261

2.  SOCS-1, a negative regulator of the JAK/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity.

Authors:  H Yoshikawa; K Matsubara; G S Qian; P Jackson; J D Groopman; J E Manning; C C Harris; J G Herman
Journal:  Nat Genet       Date:  2001-05       Impact factor: 38.330

3.  SOCS1 protects protein tyrosine phosphatases by thioredoxin upregulation and attenuates Jaks to suppress ROS-mediated apoptosis.

Authors:  J Oh; M-W Hur; C-E Lee
Journal:  Oncogene       Date:  2009-06-29       Impact factor: 9.867

Review 4.  The role of the cyclin-dependent kinase inhibitor p21 in apoptosis.

Authors:  Andrei L Gartel; Angela L Tyner
Journal:  Mol Cancer Ther       Date:  2002-06       Impact factor: 6.261

5.  Epidermal growth factor receptor-mediated proliferation of enterocytes requires p21waf1/cip1 expression.

Authors:  George Sheng; Kathryn Q Bernabe; Jun Guo; Brad W Warner
Journal:  Gastroenterology       Date:  2006-07       Impact factor: 22.682

6.  SOCS1 links cytokine signaling to p53 and senescence.

Authors:  Viviane Calabrese; Frédérick A Mallette; Xavier Deschênes-Simard; Sheela Ramanathan; Julien Gagnon; Adrian Moores; Subburaj Ilangumaran; Gerardo Ferbeyre
Journal:  Mol Cell       Date:  2009-12-11       Impact factor: 17.970

7.  Activation of the p53-p21(Cip1) pathway is required for CDK2 activation and S-phase entry in primary rat hepatocytes.

Authors:  L Wierød; C M Rosseland; B Lindeman; M P Oksvold; H Grøsvik; E Skarpen; H S Huitfeldt
Journal:  Oncogene       Date:  2007-11-19       Impact factor: 9.867

8.  Demonstration of cooperative contribution of MET- and EGFR-mediated STAT3 phosphorylation to liver regeneration by exogenous suppressor of cytokine signalings.

Authors:  Ekihiro Seki; Yuichi Kondo; Yuji Iimuro; Tetsuji Naka; Gakuhei Son; Tadamitsu Kishimoto; Jiro Fujimoto; Hiroko Tsutsui; Kenji Nakanishi
Journal:  J Hepatol       Date:  2007-11-05       Impact factor: 25.083

9.  Proliferation of human HCC cells and chemically induced mouse liver cancers requires JNK1-dependent p21 downregulation.

Authors:  Lijian Hui; Kurt Zatloukal; Harald Scheuch; Ewa Stepniak; Erwin F Wagner
Journal:  J Clin Invest       Date:  2008-11-06       Impact factor: 14.808

10.  Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production.

Authors:  Willscott E Naugler; Toshiharu Sakurai; Sunhwa Kim; Shin Maeda; Kyounghyun Kim; Ahmed M Elsharkawy; Michael Karin
Journal:  Science       Date:  2007-07-06       Impact factor: 47.728

View more
  9 in total

Review 1.  Negative Regulation of Cytokine Signaling in Immunity.

Authors:  Akihiko Yoshimura; Minako Ito; Shunsuke Chikuma; Takashi Akanuma; Hiroko Nakatsukasa
Journal:  Cold Spring Harb Perspect Biol       Date:  2018-07-02       Impact factor: 10.005

2.  Expression of SOCS1 and the downstream targets of its putative tumor suppressor functions in prostate cancer.

Authors:  Martin Chevrier; Diwakar Bobbala; Alberto Villalobos-Hernandez; Md Gulam Musawwir Khan; Sheela Ramanathan; Caroline Saucier; Gerardo Ferbeyre; Sameh Geha; Subburaj Ilangumaran
Journal:  BMC Cancer       Date:  2017-02-24       Impact factor: 4.430

3.  HJURP promotes hepatocellular carcinoma proliferation by destabilizing p21 via the MAPK/ERK1/2 and AKT/GSK3β signaling pathways.

Authors:  Tianchi Chen; Hechen Huang; Yuan Zhou; Lei Geng; Tian Shen; Shengyong Yin; Lin Zhou; Shusen Zheng
Journal:  J Exp Clin Cancer Res       Date:  2018-08-15

4.  Attenuation of MET-mediated migration and invasion in hepatocellular carcinoma cells by SOCS1.

Authors:  Yirui Gui; Md Gulam Musawwir Khan; Diwakar Bobbala; Claire Dubois; Sheela Ramanathan; Caroline Saucier; Subburaj Ilangumaran
Journal:  World J Gastroenterol       Date:  2017-09-28       Impact factor: 5.742

Review 5.  STAT3 and STAT5 Activation in Solid Cancers.

Authors:  Sebastian Igelmann; Heidi A Neubauer; Gerardo Ferbeyre
Journal:  Cancers (Basel)       Date:  2019-09-25       Impact factor: 6.639

Review 6.  p21 in Cancer Research.

Authors:  Bahar Shamloo; Sinem Usluer
Journal:  Cancers (Basel)       Date:  2019-08-14       Impact factor: 6.639

7.  Key genes and drug delivery systems to improve the efficiency of chemotherapy.

Authors:  Zally Torres-Martinez; Yamixa Delgado; Yancy Ferrer-Acosta; Ivette J Suarez-Arroyo; Freisa M Joaquín-Ovalle; Louis J Delinois; Kai Griebenow
Journal:  Cancer Drug Resist       Date:  2021-03-19

8.  SOCS1 blocks G1-S transition in hepatocellular carcinoma by reducing the stability of the CyclinD1/CDK4 complex in the nucleus.

Authors:  Jun Ding; Kangdi Xu; Suwan Sun; Chao Qian; Shengyong Yin; Haiyang Xie; Lin Zhou; Shusen Zheng; Wei Zhang
Journal:  Aging (Albany NY)       Date:  2020-02-25       Impact factor: 5.682

9.  Prognostic significance of SOCS1 and SOCS3 tumor suppressors and oncogenic signaling pathway genes in hepatocellular carcinoma.

Authors:  Md Gulam Musawwir Khan; Amit Ghosh; Bhavesh Variya; Madanraj Appiya Santharam; Awais Ullah Ihsan; Sheela Ramanathan; Subburaj Ilangumaran
Journal:  BMC Cancer       Date:  2020-08-17       Impact factor: 4.430

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.